Human Laboratory Study of ANS-6637 for Alcohol Use Disorder Save

Date Added
July 2nd, 2019
PRO Number
Pro00090068
Researcher
Sarah Book

List of Studies


Profiles_link
Keywords
Alcohol, Central Nervous System, Drug Studies, Stage II, Substance Use
Summary

This is a 6-week-long treatment study for people with Alcohol Use Disorder who want to stop or cut down their drinking. The purpose of this study is to determine whether an investigational medication, ANS-6637, affects craving for alcohol and/or alcohol drinking while taking the study drug. Participants will be randomly assigned to take one of two doses of ANS-6637 or a matched placebo.

Institution
MUSC
Recruitment Contact
Konstantin Voronin
843-792-8601
voronin@musc.edu

Establishment of a Registry for Patients Treated with Photodynamic Therapy (PDT) Save

Date Added
October 18th, 2018
PRO Number
Pro00082282
Researcher
Gerard Silvestri

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Lung, Stage I, Stage II, Stage III, Stage IV
Summary

Photodynamic therapy (PDT) is a type of treatment used to treat cancer. The purpose of this research study is to collect information on patients treated with PDT so that we can determine if patient characteristics affect their response to PDT. We will collect information about medical history, life style habits like smoking, reports from the tissue taken during biopsy, and outcome of the treatment to include in the registry.

Institution
MUSC
Recruitment Contact
Katherine Taylor
843-792-2297
taylkat@musc.edu

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin Save

Date Added
May 18th, 2018
PRO Number
Pro00077581
Researcher
Anand Sharma

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Head & Neck, Stage II, Stage III
Summary

This study is for patients that have been diagnosed with stage III-IVB Head and Neck cancer. The investigational drug in this study is MEDI4736 (Durvalumab). The purpose of the safety lead-in portion of the study is to determine whether adding the study drug MEDI4736 to radiation is safe in patients with head and neck cancer who cannot take the drug cisplatin. The purpose of the phase II/III portion is to compare any good and bad effects of usual radiation plus the study treatment, MEDI4736 (durvalumab), to the usual therapy of radiation plus cetuximab in patients with head and neck cancer who cannot take the drug cisplatin. Participants in the safety lead-in portion can expect to be in this study for approximately 2.5 years. Participants in the Phase II/III portion can expect to be in the study for up to 32 weeks, and then followed by their study doctor to monitor for side effects every year.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Altering memories that increase risk of relapse in alcohol use disorders: A translational clinical neuroscience pilot investigation of a novel pharmacological agent. Save

Date Added
February 6th, 2018
PRO Number
Pro00073523
Researcher
Michael Saladin

List of Studies


Profiles_link
Keywords
Alcohol, Drug Studies, Stage II
Summary

The proposed study will employ treatment-seeking AUD individuals who will be randomly assigned to receive either 15 mg of rapamycin (sirolimus) or placebo immediately after the first of two alcohol cue exposure sessions scheduled to occur on consecutive days. Subjective responses (i.e., craving) and physiological (heart rate & skin conductance) reactivity will be obtained before, during and after cue presentations in both sessions. The durability of any observed treatment effects will be assessed in a Follow-up session performed approximately 10 days following completion of the second session. Treatment effects on self-report measures of drinking behavior during the approximately 10 days preceding the Follow-up session will also be assessed.

Institution
MUSC
Recruitment Contact
Brittany Frasier
843-792-6984
frasibri@musc.edu

Change_preferences

-- OR --

Create_login